PHD Biosciences
We are developing an enzyme inhibitor with pico-‐molar binding affinity and minimal toxicity as a once daily, oral therapeutic for the treatment of triple-‐negative breast cancer. Nanomedics LLC Team: Michael Isaacman Andrew Mahon
Read MoreSveikatal
Sveikatal, is focused on the management of oral cancer using a novel retinoid therapy, which acts through pathways controlled by Vitamin A and complements current therapies. Sveikatal Team: John Wagner, PhD Amy Chen, CFO
Read MoreNomoCan Pharmaceuticals
Utilizing a novel immunologic approach, NomoCan Pharmaceuticals is developing a targeted therapy for the treatment and prognosis of the most aggressive human cancer, pancreatic cancer. NomoCan Pharmaceuticals Team: Ehsan Sarafraz-Yazdi, PhD Kamyar Neshvadian, FRM
Read MoreZakan Theraputics
Zakan Therapeutics — A biological therapeutic that can directly attack metastatic cancer cells by delivering a payload of anti-cancer compounds while bypassing healthy cells. Zakan Theraputics Team: Arthee Jahangir Benjamin Caballero
Read MoreTaithera, Inc.
Aithera is a revolutionary nanomedicine bone targeted drug delivery controlled release platform technology for the treatment of musculoskeletal conditions focused initially on fracture healing & bone cancer (osteosarcoma is our first oncology target). Aithera Team: Seth Harlem, CEO Mo Chen, PhD, CSO
Read MoreMassive Bio
Massive Bio provides cutting-edge concierge advisory services for precision oncology to cancer patients treated at community practices. Massive Bio Team: Selin Kurnaz, PhD. – CEO
Read MoreVitrisa Theraputics
Platform technology for rapid development of highly stable, high affinity clinic ready ligands called aptamers. Vitrisa Theraputics Team: Arijit Bhowmick Matthew Levy
Read MoreInnovene, Inc.
Innovene has designed a new class of medications from safe plant-derived components; TriCurin will target the unmet medical need of treating patients with oncogenic human papillomavirus infections. Innovene Team: Mario Castellanos, MD, Co-Founder and President Alia Kozlova
Read MoreTEZCAT Biologics
TEZCAT is developing a biologics-based therapeutic approach to treat mutant Ras cancers, such as colorectal cancer. TEZCAT team: CEO – Alex Efron CSO – Craig Ramirez, Ph.D. Ops. Mgr – Andy Hauser, Ph.D.
Read MoreVesselon
Vesselon, Inc. is developing novel therapeutic immuno-oncology complexes that are protected in circulation and actively targeted to tumors using an FDA approved lipid microsphere drug as the backbone of its encapsulated drug/drug platform technology. Furthermore, the complexes are formed at the time of administration (rather than at the drug manufacturing stage) enabling the creation of…
Read More